Get started
Work

Abstract CT079: Durable responses to avelumab (anti-PD-L1) in patients with Merkel cell carcinoma progressed after chemotherapy: 1-year efficacy update

Year: 2017
Type: conference-abstract
DOI: 10.1158/1538-7445.am2017-ct079
Authors: Howard L. Kaufman, Jeffery S. Russell, Omid Hamid, Shailender Bhatia, Patrick Terheyden, Sandra P. D’Angelo, Kent C. Shih, Celeste Lebbé, Michele Milella, Isaac Brownell, Karl D. Lewis, Jochen H. Lorch, Anja von Heydebreck, Lisa Mahnke, Paul Nghiem
Institutions: Rutgers, The State University of New Jersey, Rutgers Cancer Institute, Moffitt Cancer Center, Angeles Clinic and Research Institute, University of Washington, University of Washington Medical Center, University of Lübeck, Memorial Sloan Kettering Cancer Center, Cornell University, Sarah Cannon, Tennessee Oncology, Inserm, Hôpital Saint-Louis, HIPI - Immunologie humaine, physiopathologie et immunithérapie, Instituto Nazionale Tumori Regina Elena, National Cancer Institute, University of Colorado Denver, Dana-Farber Cancer Institute, Merck KGaA, Darmstadt (Germany), Merck Healthcare KGaA, Darmstadt (Germany)
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: closed
OpenAlex ID: W2740937461
Cites:
Cited by: 24
Related to: 10